Sanofi eyes RSV antibody for its next blockbuster while Dupixent brings in record sales

Sanofi’s RSV antibody Beyfortus is still on track to reach blockbuster status this year as the company expands manufacturing capacity, according to remarks made Thursday …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Opinion | Weight Stigma Is Bad Medicine

Zha is a physician and a nonfiction writer. It’s summer 2024, yet Lady Gaga still had to fight rumors about her “looking pregnant.” “Can we

July 5, 2024

Outsized Death Risk for Women With Afib After Heart Surgery

After cardiac surgery, women were particularly vulnerable to poor outcomes in the long run if the most common procedural complication had occurred, according to a

August 22, 2024

Biohaven’s $230M offering; Plus, three new PIPEs

Read on for news about Benitec Biopharma, Korro Bio, Zura Bio, Ocular Therapeutix and SK biopharmaceuticals: Biohaven to seek $230M public offering: The company’s offering

April 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.